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Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic infection that 
is almost invariably fatal unless treated. It is a neglected tropical disease that occurs in 
sub-Saharan Africa. 
The infection is transmitted to humans through the bite of an infected tsetse fly. The 
parasite multiplies in the lymph and blood, causing unspecific symptoms and signs 
(first-stage or haemo-lymphatic stage) and, over time, crosses the blood–brain barrier to 
infect the central nervous system (second-stage or meningo-encephalitic stage). Brain 
involvement causes various neurological disturbances, including sleep disorders (hence 
the name “sleeping sickness”), progression to coma and, ultimately, death.
The disease has two forms: the slowly progressing form (gambiense HAT), caused by 
infection with Trypanosoma brucei gambiense, found in western and central Africa 
(currently 98% of cases); and the faster progressing form (rhodesiense HAT), caused 
by infection with T. b. rhodesiense, in eastern and southern Africa (responsible for the 
remainder of cases). All age groups and both sexes are at risk of both forms of HAT, 
although prevalence is higher in adults than in children.
The incidence of the disease is declining in response to intensive surveillance and 
control in endemic areas. As a result, HAT is among the neglected tropical diseases 
targeted by the World Health Organization (WHO) for elimination. WHO maintains 
exhaustive records of all declared cases; in 2018, a historically low number of cases  
(< 1000) was reported.  
The remarkable progress in the control of gambiense HAT has relied on case-finding and 
curative treatment, a strategy that interrupts transmission by depleting the reservoir of 
parasites in humans. This has been combined occasionally with vector control activities. 
The subject of these guidelines, therefore, is of utmost importance for the continuation 
of progress to eliminate HAT.
Executive summary
ix
Methodology: The guidelines were developed in accordance with the 
recommendations of the WHO Guidelines Review Committee.1  A WHO steering 
committee defined the scope of the guidelines and formulated the questions 
to be addressed in PICO (population, intervention, comparator and outcomes) 
format. A specialized team was externally commissioned to conduct a systematic 
review of the literature and to rate the evidence following the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluation) methodology. A 
guideline development group comprising experts with pertinent knowledge and 
experience, relevant geographical representation and without conflicts of interest 
met in Geneva in December 2018 to scrutinize the available evidence and formulate 
recommendations based on the GRADE approach. The following elements were 
considered: the balance between desirable and undesirable effects, certainty of the 
evidence, resource implications, equity, acceptability and feasibility. These elements 
were used to build the evidence-to-decision tables. The draft guideline was critically 
reviewed via remote collaboration by members of the guideline development group, 
the WHO steering committee, the guideline methodologist and the peer reviewers 
before submission to the WHO Guidelines Review Committee.
The recent approval of a new medicine (fexinidazole) for the treatment of gambiense 
HAT has opened new possibilities for the management of cases and thus warrants the 
new WHO recommendations contained herein. While studies of fexinidazole and other 
therapies are ongoing, these guidelines are considered interim guidelines until new 
information becomes available.2
This document focuses on the management of patients affected by gambiense HAT and 
constitutes an update to the WHO therapeutic guidance issued in 2013.
The main changes in recommendations concern the criteria and methods for deciding 
the treatment among the new set of therapeutic options and the particular conditions 
that apply to treatment with fexinidazole, as outlined below. Because HAT is a serious, 
life-threatening disease and because the efficacy of fexinidazole depends on swallowing 
the medicine after an appropriate intake of food as well as on completing the full 10-day 
treatment schedule, the recommendations regarding fexinidazole administration are 
considered key elements that must be carefully followed. When the conditions listed 
in these guidelines are not met for any individual patient, the alternative available 
treatments should be prescribed.
1 Handbook for guideline development, 2nd edition. Geneva: World Health Organization; 2014. (http://apps.who.int/
medicinedocs/documents/s22083en/s22083en.pdf, accessed June 2019).
2 Interim guidelines are produced when WHO is asked to provide guidance when the available data and information are 
most certainly incomplete, especially if additional data are anticipated in the near future.
xSummary of WHO recommendations for the treatment of gambiense HAT
Patient stratification WHO recommendations Strength of recommendation
Quality of 
evidence
Patients who can be 
managed without 
lumbar puncture (LP)
Patients aged ≥ 6 years and weighing ≥ 20 kg who meet both 
of the following conditions:
   low index of suspicion of severe disease based on clinical 
judgement; and
  high confidence that the patient will have appropriate 
follow-up to detect relapse early,
will not require LP stratification and may be treated 
preferentially with fexinidazole. .
Conditional. Very low
Patients requiring 
lumbar puncture (LP)
Patients who do not meet the above criteria will require LP 
stratification. 
Patients who require LP stratification but do not receive LP, 
and those whose LP results are unreliable, will be treated 
preferentially with NECT. 
Patients who reject or do not tolerate fexinidazole may need a 
LP to decide between pentamidine and NECT.
Conditional. Very low
Type of patient WHO recommendations Strength of recommendation
Quality of 
evidence
Patients aged ≥ 6 years 
and body weight ≥ 20 kg
AND
in first-stage or non-
severe second-stage 
(WBC in CSF < 100/µL)
Use fexinidazole over pentamidine in patients with first-stage 
HAT and over NECT in patients with second-stage HAT with 
WBC in CSF < 100/µL. 
Conditional Very low 
(first-stage),
Low 
(second-stage)
Patients in severe 
second-stage 
(WBC in CSF ≥ 100/µL)
Use NECT in preference to fexinidazole. Conditional Low
Children aged < 6 
years or body weight 
< 20 kg
Use pentamidine in first-stage and NECT in second-stage. Conditional Very low
Pregnant women
Former WHO recommendations apply. Fexinidazole can be 
given after the 1st trimester.
Conditional Very low
xi
Fexinidazole 
administration
WHO recommendations Strength of recommendation
Quality of 
evidence
Food intake: For fexinidazole to be absorbed in therapeutic levels it must be taken in a 
fed condition (i.e. after a substantial meal). As a condition for prescribing fexinidazole, 
the prescriber must have confidence in the availability of food for the patient, which will 
be eaten directly before the drug administration daily.
Conditional Low
Directly observed treatment: Each intake of fexinidazole must be supervised by a trained 
health staff who must ensure that the patient is in a fed condition.
Conditional Very low
Outpatient administration (under daily supervision) can be decided in consultation with 
the patient, his/her family and clinicians, taking into account the following factors:
   convenience to the patient and the family (e.g. distance and costs);
  development of side-effects interfering with treatment compliance;
  existing comorbidities; and
  capacity of the healthcare system for supervised administration as an outpatient.
Hospitalization should be mandatory in the following cases:
   patients with psychiatric disorders;
  children with body weight < 35 kg; 
  patients with ≥ 100 WBC treated (exceptionally) with fexinidazole; and
  risk of poor compliance with treatment.
Conditional for 
either inpatient 
or outpatient
Very low
CSF, cerebrospinal fluid; LP, lumbar puncture; NECT, nifurtimox–eflornithine combination treatment; WBC, white blood cell 
xii
This new set of recommendations is integrated into a new algorithm for the 
management of gambiense HAT, as represented in the figure below.
CSF, cerebrospinal fluid; DOT, directly observed treatment; NECT, nifurtimox–eflornithine combination therapy; WBC, white blood cell
a Presence of symptoms and signs consistent with severe second-stage HAT, as detailed in Annex 1.  
b If the health facility has capacity for supervised administration as an outpatient.
Algorithm of WHO recommendations for the management of gambiense HAT
Patient diagnosed with HAT
No Yes
Clinical assessment:
severe HAT is suspected a
≥ 6 years old, AND
≥ 20 kg body weight
Lumbar puncture
≥ 100 WBC/µL< 100 WBC/µL Not done
• Confidence in concomitant food intake
• Confidence in full adherence
• No psychiatric disorders (history or acute)
• ≥ 35 kg body weight
< 6 years old, OR
< 20 kg body weight
≤ 5 WBC/µL,
no CSF tryps
6–99 WBC/µL,  
or CSF tryps
Fexinidazole  
outpatient daily DOTb 
Fexinidazole 
hospitalized
Pentamidine NECT
No
Yes
Yes to all No to any
1The approval in 2018 of a new medicine (fexinidazole) for the treatment of gambiense 
HAT opens new possibilities for the management of cases and thus warrants updating 
of the existing recommendations for treatment of HAT. While studies of fexinidazole and 
other drugs are ongoing, the present guidelines are considered interim guidelines until 
new information becomes available.
This document focuses on the management of patients affected by gambiense HAT 
and constitutes an update and a complement to the existing WHO guidance and 
recommendations, namely:
   WHO (2013). Treatment. In: Control and surveillance of human African 
trypanosomiasis: report of a WHO Expert Committee. Geneva: World Health 
Organization (WHO Technical Report Series, no. 984);150–188. 1
  WHO (2015). Medicines for the treatment of 1st stage African trypanosomiasis. In: The 
selection and use of essential medicines: report of the WHO Expert Committee, 2015 
(including the 19th WHO Model List of Essential Medicines and the 5th WHO Model 
List of Essential Medicines for Children). Geneva: World Health Organization (WHO 
Technical Report Series, no. 994);4372
1.1. Goal
The goal of these guidelines is to provide updated evidence-based recommendations 
on therapeutic choices to ensure the best possible treatment for individuals infected 
with Trypanosoma brucei gambiense, taking into account the current therapeutic 
options and the different epidemiological, clinical and operational scenarios. 
1.2. Target audience
These guidelines are primarily targeted at policy-makers in ministries of health working 
in countries where HAT is endemic3  to assist in updating national HAT policies and 
treatment guidelines. They are intended also as a resource for medical staff caring for 
patients with HAT infection. The guidelines take into consideration the fact that HAT 
mostly occurs in remote areas and is managed in health facilities with limited resources, 
by lesser trained medical staff (e.g. clinical officers, nurses, nursing aids).
1 Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee. Geneva: World Health 
Organization; 2013 (WHO technical report series; no. 984; (https://apps.who.int/iris/bitstream/handle/10665/95732/978924
1209847_eng.pdf, accessed June 2019).
2 The selection and use of essential medicines: report of the WHO Expert Committee, 2015 (including the 19th WHO 
Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Geneva: World Health 
Organization (WHO technical report series; no 994 (https://apps.who.int/iris/bitstream/handle/10665/189763/9789241209
946_eng.pdf, accessed June 2019).
3 Countries endemic for gambiense HAT: Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, 
Democratic Republic of the Congo, Côte d’Ivoire, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, 
Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, South Sudan, Togo, Uganda.
1. Introduction
21.3. Guiding principles
The objective of WHO is the attainment by all peoples of the highest possible level of 
health. The present guidelines have been developed in accordance with this principle 
and that of the United Nations Universal Declaration of Human Rights.4 People infected 
with T. b. gambiense or T. b. rhodesiense may come from vulnerable or marginalized 
groups with poor access to health care and may be subject to discrimination and 
stigmatization. It is therefore essential that these guidelines and the policies derived 
therein incorporate basic human rights and equity, including the right to confidentiality 
and informed decision-making when considering whether to be screened and treated 
for HAT.
High-quality care and treatment for persons with HAT require adequate supplies of 
medication and specially trained staff to ensure complete and correct administration of 
the appropriate medicine. Case management depends on the sub-species of causative 
trypanosome and on case presentation, and thus requires access to appropriate 
laboratory facilities for disease staging and to assess the response to treatment. 
Observance of the fundamental ethical principles of good clinical practice (respect for 
persons, beneficence and justice) should therefore extend to all health personnel caring 
for HAT patients.
1 The Universal Declaration of Human Rights. Geneva: United Nations; 1948 (https://www.ohchr.org/EN/UDHR/Documents/
UDHR_Translations/eng.pdf, accessed June 2019).
32. Methodology and process of 
developing the guidelines
These WHO guidelines were developed following the process recommended by the 
WHO Guidelines Review Committee, including systematic evidence reviews, rating of 
evidence following the GRADE methodology, use of formal procedures and rules for 
selection of experts, management of conflicts of interest and the GRADE methodology 
for decision-making and to formulate recommendations. Details of the methodology are 
provided in Annex 2. 
43. Background
3.1. Epidemiology and burden
Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic infection that 
is almost invariably fatal unless treated. Throughout the 20th century the disease caused 
devastating epidemics. However, as a result of sustained and coordinated efforts over 
the past 25 years, the number of reported cases has fallen to historically low levels (< 
1000 in 2018). HAT is a neglected tropical disease that occurs in sub-Saharan Africa, 
within the distributional limits of its vector, the tsetse fly. 
After a human is bitten by an infected fly (both male and female tsetse can transmit 
HAT infection), the parasite multiplies in the lymph and the blood, causing unspecific 
symptoms and signs such as headache, fever, weakness, joint and muscle pain and 
lymphadenopathy (first-stage or haemo-lymphatic stage). People who become infected 
may or may not show noticeable signs of illness immediately, but over time the parasite 
crosses the blood–brain barrier and infects the central nervous system (second-
stage or meningo-encephalitic stage). Brain involvement causes various neurological 
changes, including sleep disorders (hence the name “sleeping sickness”), deep sensory 
disturbances, abnormal tone and mobility, ataxia, psychiatric disorders, seizures, coma 
and, ultimately, death.
Two forms of the disease exist: the slowly progressing form, caused by infection with 
T. b. gambiense, found in western and central Africa (gambiense HAT); and the faster 
progressing form, caused by T. b. rhodesiense infection, in eastern and southern Africa 
(rhodesiense HAT).
Although the geographical area infested with tsetse flies is very large, HAT has 
a markedly focal distribution that results from complex and as yet incompletely 
understood interactions between parasite, vector, host and the environment. The 
disease usually occurs in rural areas where human–tsetse contact is frequent, but 
periurban areas can also be affected. People become infected while farming, fishing, 
hunting, collecting water or wood, or during other activities that expose them to tsetse 
flies. All age groups and both sexes are at risk, although prevalence is higher in adults 
than in children. Sex distribution varies in relation to gender-specific at-risk activities.
Human beings are the main reservoir of T. b. gambiense, while domestic and wild 
animals constitute the reservoir for T. b. rhodesiense. Although domestic and wild 
animals can also host T. b. gambiense, their epidemiological role appears minor in 
comparison with the human reservoir.
The World Health Organization (WHO) maintains exhaustive records of all declared 
cases. In 2018, a historically low number of cases (< 1000) was reported, most of which 
were caused by infection with T. b. gambiense (Figure 1). In response to the declining 
incidence of HAT, WHO has included the disease among those targeted for elimination 
5as a public health problem by 2020, as stated in the WHO roadmap for control, 
elimination and eradication of neglected tropical diseases.1  A further target is to fully 
eliminate the occurrence of gambiense HAT (i.e. zero cases) by 2030.
At its tenth meeting in 2017, the Strategic and Technical Advisory Group for Neglected 
Tropical Diseases2 defined the “elimination of HAT as a public health problem” with two 
main indicators: 
   reduction of the total number of new cases reported worldwide < 2000 by 2020; and
  90% reduction of the total area at risk reporting ≥ 1 case/10 000 people per year by 
2020, from the 2004 baseline levels.
Figure 1. Progress in the elimination of HAT, by number of cases, 2000–2020 
Gambiense HAT Rhodesiense HAT         WHO roadmap benchmarks
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The process of validation of the elimination of HAT was established according to 
the Generic framework for control, elimination and eradication of neglected tropical 
diseases.3
The remarkable progress in the control of gambiense HAT has relied on depleting the 
reservoir of parasites in humans, detecting cases and ensuring curative treatment, a 
strategy that has proven capable of interrupting transmission. This has been combined 
occasionally with vector control activities. 
1 Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: 
World Health Organization; 2012 (https://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf, accessed 
June 2019).
2 10th meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases. Geneva: World Health 
Organization; 2017 (http://www.who.int/neglected_diseases/NTD_STAG_report_2017.pdf, accessed June 2019).
3 Generic framework for control, elimination and eradication of neglected tropical diseases. Geneva: World Health 
Organization; 2015 (http://www.who.int/neglected_diseases/resources/NTD_Generic_Framework_2015.pdf, accessed June 
2019).
6Therefore, for progress towards HAT elimination to continue, it is crucial that these 
guidelines are applied correctly in order to maximize the chances that every patient 
receives effective curative treatment.
3.2. Case management until now 
To date, treatment for gambiense HAT has relied on four medicines (eflornithine, 
melarsoprol, nifurtimox and pentamidine) and for rhodesiense HAT three medicines 
(melarsoprol, pentamidine and suramin).1 The drugs are donated by manufacturers 
and distributed by WHO free of charge to ensure that all HAT patients worldwide have 
access to the most effective treatment available. 
The choice of treatment has depended on the sub-species of causative trypanosome (T. 
b. gambiense or T. b. rhodesiense) and on the stage of the disease (first-stage: ≤ 5 WBC/
µL and no trypanosomes in CSF; second-stage: > 5 WBC/µL and/or trypanosomes in 
CSF). The medicines available to treat first-stage (haemo-lymphatic) disease generally 
do not cure second-stage (meningo-encephalitic) disease. Although effective, the 
medicines used to treat the meningo-encephalitic stage cannot be justified for 
treatment of the haemo-lymphatic stage because they tend to be more toxic and more 
cumbersome to administer.
Until now, the first-line treatment for gambiense HAT was pentamidine for first-stage 
disease and nifurtimox–eflornithine combination therapy (NECT) for second-stage 
disease. Eflornithine and melarsoprol monotherapies, the second- or third-line 
alternatives, were rarely used.
3.3. Changes in case management established in these guidelines 
These guidelines present a revised therapeutic protocol to include fexinidazole, a new 
medicine that received regulatory approval for treatment of gambiense HAT in 2018.2  
The characteristics of this new therapeutic alternative open the way for significant 
modifications in the management of gambiense HAT cases, such as removing the need 
for systematic lumbar punctures for staging and also the need for injectable treatments 
in specific groups of patients.
The main characteristics of fexinidazole are given in section 5, and the supporting 
evidence is described in detail in Web appendix 1 (Systematic Evidence Review), as 
well as in the public assessment report of the European Medicines Agency published in 
November 2018.3
The recommendations of the WHO Guideline Development Group are summarized in 
the Executive Summary and can be consulted in full in Web appendix 2 (Evidence to 
Decision tables).
1 See: Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee. Geneva: World 
Health Organization; 2013 (WHO technical report series; no. 984; (https://apps.who.int/iris/bitstream/handle/10665/95732/
9789241209847_eng.pdf, accessed June 2019).
2 Positive scientific opinion of the European Medicines Agency (EMA) in November 2018 and marketing authorization in the 
Democratic Republic of the Congo in December 2018.
3 Product information 15/11/2018: fexinidazole Winthrop H-W-2320. Amsterdam: European Medicines Agency; 2019 
(https://www.ema.europa.eu/en/fexinidazole-winthrop-h-w-2320, accessed June 2019).
7Summary efficacy and safety data supporting the changes
  For first-stage HAT, in two open-label, single-arm studies in adults and children aged 
≥ 6 years, respectively, fexinidazole treatment success rates at 18 months were 97.9% 
and 98.6%, mortality rates 1.6% and 1.4%, adverse event rates 93.1% and 88.4%, 
and serious adverse event rates 9.0% and 7.2%. These outcomes appear to be more 
favourable than those reported for pentamidine, although the length of follow-up 
differed and adverse events were of different types.
  For second-stage HAT, data from a randomized clinical trial comparing fexinidazole 
with NECT showed that in patients with > 100 WBC/µL of CSF (severe second-stage), 
the treatment success rates at 18 months were 86.9% with fexinidazole versus 98.7% 
with NECT, significantly in favour of NECT. In patients with ≤ 100 WBC/µL of CSF, 
success rates were 98% with fexinidazole and 95.9% with NECT, with no significant 
difference. The overall safety data were not substantially different for both treatments.
 
3.4. Relevance of older guidelines
The present guidelines deal with case management and treatment of gambiense HAT 
patients only. For rhodesiense HAT, the management of patients is still covered by the 
guidelines published by WHO in 2013 which remain relevant also for other aspects of 
HAT control and surveillance. 
84. Case definitions, assessment 
of patients and treatment choice
Clinical symptoms and signs, such as prolonged fever, swollen lymph nodes or 
neurological signs, can raise suspicion of HAT but are not sufficient to establish a 
diagnosis. Relatively simple, reliable antibody tests exist for screening populations at risk 
of T. b. gambiense infection. As clinical symptoms and signs or serological tests are not 
sufficiently specific, parasitological confirmation by observation of trypanosomes in body 
fluids is generally required.
4.1. Case definitions for treatment 
Cases of HAT have been categorized for treatment according to the above 
considerations as:
Confirmed case: An individual in whom trypanosomes have been observed.
Case suspected by serological findings: An individual with an epidemiological risk for 
HAT in whom anti-trypanosomal antibodies have been detected with a serological test 
but in whom trypanosomes have not been observed.
All confirmed cases require treatment. Cases suspected by serology may be treated or 
not, depending on the national protocol, which usually sets specific conditions, such 
as plasma titration, other more specific serological tests (trypanolysis), and clinical and 
epidemiological parameters.
The following sections (4.2–4.5) apply in situations where treatment with fexinidazole is 
available and technically feasible.
4.2. Disease categorization for treatment 
HAT has been categorized classically as first-stage or second-stage disease for the main 
practical purpose of guiding therapeutic choices1 (see section 3.2). 
Currently, with the introduction of fexinidazole which is effective for both disease stages 
with a limit established at CSF (cerebrospinal fluid) WBC (white blood cell) counts ≥ 100/
µL, a new sub-category is proposed, as follows:
1 The historically firmer criterion for staging has been the 5 WBC/µL in CSF cut-off, discriminating the first and second 
stages. However, depending on the risk–benefit of the available therapeutic options over time, different cut-offs were used 
for gambiense HAT, sometimes defining three disease stages (e.g. first, intermediate, and second stage).
9  haemo-lymphatic stage (first-stage): ≤ 5 WBC/µL AND no trypanosomes in CSF;
  meningo-encephalitic stage (second-stage): > 5 WBC/µL with or without 
trypanosomes in CSF; and 
  severe meningo-encephalitic stage (severe second-stage): ≥ 100 WBC/µL with or 
without trypanosomes in CSF.
4.3. Categorization of patients: clinical examination and situations 
where CSF examination is needed
Once a patient has been defined as a HAT case to be treated, a detailed clinical 
assessment must be carried out by a health professional who has training and capacity 
to establish the presence or absence of symptoms and signs which can raise suspicion of 
severe meningo-encephalitic HAT.
The main symptoms and signs consistent with severe meningo-encephalitic HAT 
are: mental confusion, abnormal behaviour, logorrhea, anxiety, ataxia, tremor, motor 
weakness, speech impairment, abnormal gait, abnormal movements and seizures. 
Although sleep disorder is very common in severe HAT, it is also frequent in non-severe 
HAT, and thus this feature alone is not considered sufficient for a suspicion of severe 
HAT. A summary, field-adapted description is provided in Annex 1.
A patient who does NOT present with any of the above symptoms and signs is assumed 
at low probability to be in the severe meningo-encephalitic stage and a lumbar puncture 
is not needed to guide the choice of treatment.
A patient who presents with any of the above symptoms and signs, as described in 
Annex 1, is considered potentially to be in the severe meningo-encephalitic stage and 
a lumbar puncture followed by a CSF examination are required in order to categorize 
the meningo-encephalitic stage and establish the best treatment option. If the lumbar 
puncture is not done for any reason (e.g. the patient refuses) or the results cannot be 
interpreted (e.g. presence of red blood cells > 100/µL), then the first-choice treatment is 
NECT.
A patient aged < 6 years or body weight < 20 kg (i.e. a patient for whom fexinidazole is 
not indicated) must undergo a lumbar puncture and a CSF examination to determine the 
treatment choice. 
4.4. First-choice treatment
The first-choice treatment is determined by a two-step assessment as described in the 
algorithm shown in Figure 2. The first step is the clinical examination and the second 
step is the CSF examination (lumbar puncture) which is required only for patients with 
clinical symptoms and signs suggestive of severe meningo-encephalitic stage. For 
patients undergoing lumbar puncture, the possible treatment scenarios are:
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For patients aged ≥ 6 years and body weight ≥ 20 kg: 
   < 100 WBC/µL CSF --> fexinidazole
  ≥ 100 WBC/µL CSF --> NECT
  CSF WBC not available --> NECT
For patients aged < 6 years or body weight < 20 kg: 
   ≤5 WBC/µL CSF, no trypanosomes --> pentamidine
  > 5 WBC/µL CSF or trypanosomes --> NECT
  CSF WBC not available --> NECT.
Fexinidazole is therefore the first-choice treatment in patients aged ≥ 6 years and body 
weight ≥ 20 kg presenting without clinical features consistent with severe meningo-
encephalitic HAT or presenting with < 100 WBC/µL in CSF. It is recommended that 
fexinidazole be prescribed only when there is high confidence that the patient will have 
appropriate follow-up to detect relapse early.
Figure 2. Algorithm of WHO recommendations on the management of persons with gambiense HAT
CSF, cerebrospinal fluid; DOT, directly observed treatment; NECT, nifurtimox–eflornithine combination therapy; WBC, white blood cell
a Presence of symptoms and signs consistent with severe second-stage HAT, as detailed in Annex 1.  
b If the health facility has capacity for supervised administration as an outpatient.
Patient diagnosed with HAT
No Yes
Clinical assessment:
severe HAT is suspected a
≥ 6 years old, AND
≥ 20 kg body weight
Lumbar puncture
≥ 100 WBC/µL< 100 WBC/µL Not done
• Confidence in concomitant food intake
• Confidence in full adherence
• No psychiatric disorders (history or acute)
• ≥ 35 kg body weight
< 6 years old, OR
< 20 kg body weight
≤ 5 WBC/µL,
no CSF tryps
6–99 WBC/µL,  
or CSF tryps
Fexinidazole  
outpatient daily DOTb 
Fexinidazole 
hospitalized
Pentamidine NECT
No
Yes
Yes to all No to any
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Pentamidine is the first-choice treatment in patients aged < 6 years or body weight < 20 
kg presenting with ≤ 5 WBC/µL in CSF and no trypanosomes in CSF.
NECT is the first-choice treatment in patients presenting clinical features consistent with 
severe meningo-encephalitic HAT with ≥ 100 WBC/µL in CSF or where CSF data are 
unavailable. It is also the first choice of treatment for patients aged < 6 years or body 
weight < 20 kg presenting with > 5 WBC/µL or trypanosomes in CSF.
4.5. Second-choice and rescue treatments
A second-choice treatment is the alternative treatment recommended in cases where 
the first-choice treatment is not available or is not appropriate for a particular patient for 
other reasons. It should not be confused with rescue treatment, which is given in cases 
of treatment failure (see section 12).
Second choice to fexinidazole: pentamidine (if ≤ 5 WBC/µL and no trypanosomes in 
CSF) or NECT (if > 5 WBC/µL or trypanosomes in CSF).
Second choice to NECT: fexinidazole.
Age, body weight
Clinical 
examination
CSF findings
Treatment
1st choice 2nd choice Rescuea
< 6 years or 
< 20 kg
≤ 5 WBC/µL, no 
trypanosomes 
pentamidine – NECT
> 5 WBC/µL, or 
trypanosomes
NECT eflornithine NECT-long 
≥ 6 years and 
≥ 20 kg
No suspicion of 
severe HAT
LP not needed fexinidazole
– LP needed –
pentamidine 
(first-stage) 
or 
NECT 
(second-stage)
NECT
Suspicion of severe 
HAT
< 100 WBC/µL fexinidazole
pentamidine 
(first-stage) or 
NECT 
(second-stage)
NECT
≥ 100 WBC/µL
or failed LP
NECT fexinidazole
NECT-long 
or melarsoprol
 
LP, lumbar puncture; NECT-long: nifurtimox (15 mg/kg per day) in three doses for 10 days; eflornithine (400 mg/kg per day) in two infusions for 14 days; WBC, white 
blood cell
a See section 12 for more details
Table 1. Summary of treatment choices for patients with gambiense HAT
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5. Fexinidazole
As an oral treatment, fexinidazole has important advantages over other treatment 
options that require labour-intensive intravenous or intramuscular infusions, which carry 
a risk of catheter or needle-related infection and necessitate systematic hospitalization. 
In addition, oral treatment implies cost reductions both for the health system in terms 
of accessory materials and logistics and for some patients who may be able to access 
treatment at shorter distances from their home.
When taken correctly for 10 days,1 fexinidazole presents equivalent efficacy to 
pentamidine in first-stage HAT and to NECT in second-stage HAT with CSF WBC counts 
< 100/µL. The efficacy is inferior to NECT in the severe second-stage, defined by a CSF 
WBC count ≥ 100 /µL.2
If fexinidazole is not taken at the right dosage for the full course of treatment, or without 
the appropriate concomitant food intake, the efficacy is unknown and probably lower 
than that reported in clinical trials. 
The medicine is a nitroimidazole derivative and it is suggested that it acts through 
bioactivation by parasite nitroreductase enzymes to generate reactive amines and/or 
other metabolites that exert toxic effects on the trypanosomes. Fexinidazole is rapidly 
absorbed, and food intake markedly increases the bioavailability. It is metabolized to two 
active metabolites (fexinidazole sulfoxide (M1) and fexinidazole sulfone (M2)). Most of 
the M1 and M2 are excreted in the faeces within the first 48 and 120 hours after dosage, 
respectively. Only a small fraction (< 3%) of the dose administered is recovered in the 
urine.
5.1. Presentation
Fexinidazole (Fexinidazole Winthrop) is supplied as pale-yellow tablets containing 600 
mg of active compound. The full treatment is included in a wallet, of which there are two 
types: a wallet containing 14 tablets for children (aged ≥ 6 years and body weight 20–34 
kg) and a wallet with 24 tablets for adults (body weight ≥ 35 kg).
5.2. Posology 
Fexinidazole must be taken once daily for 10 days, with a loading dose over the first four 
days and a maintenance (lower) dose over the last six days. Tablets must be taken with 
food, during or immediately after the main meal of the day, and preferably at the same 
time each day.
The dosage varies according to the patient’s body weight, determining two categories 
(cut-off 35 kg), that receive a different number of tablets. All tablets contain 600 mg of 
the active ingredient.
1 Current data are limited to oral fexinidazole taken during 10 days under strict supervision in clinical trials settings.
2 Product information 15/11/2018: fexinidazole Winthrop H-W-2320. Amsterdam: European Medicines Agency; 2019 
(https://www.ema.europa.eu/en/fexinidazole-winthrop-h-w-2320, accessed June 2019).
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Body weight No. of tablets (600 mg) to be taken once daily with food Duration
≥ 35 kg
Loading phase 1800 mg (3 tablets) 4 days 
Maintenance phase 1200 mg (2 tablets) 6 days
20–34 kg
Loading phase 1200 mg (2 tablets) 4 days 
Maintenance phase 600 mg (1 tablet) 6 days
Table 2. Posology of fexinidazole in adults and children aged ≥ 6 years 
The tablets should not be broken or crushed, i.e. they should be swallowed whole. 
If the treatment schedule is interrupted or the patient vomits after swallowing 
fexinidazole, the trained health care staff responsible for the treatment should decide 
how to continue the treatment based on the time point of the interruption within the 
10-day schedule or the timing of the vomiting. The following general rules apply:
Missed doses: For the treatment to be considered acceptable (although not ideal), a 
minimum of 7 doses must be correctly taken, including the complete loading phase (D1–
D4), plus at least 3 doses during the maintenance phase (D5–D10). 
If a dose is missed (i.e. not taken on the assigned day), normal dosing should resume the 
following day until the full course (10 days) is complete.
  If a dose is missed during the loading phase (D1–D4), and > 1 day has passed, the 
treatment must re-start from zero.
  If a dose is missed during the maintenance phase (D5–D10), the rule is to ensure that 
a minimum of 3 doses (out of the 6 doses of the maintenance phase) are correctly 
taken
If a second dose is missed (i.e. the patient does not come, does not swallow the tablets, 
or does not present in a fed condition), the patient should be considered unreliable to 
take oral fexinidazole and an alternative treatment should be established.
Vomiting: If a first event of vomiting occurs after receiving fexinidazole, do not re-dose 
the same day. Consider giving metoclopramide if available.
  If the vomiting happened less than 2 hours after fexinidazole intake, there is risk of 
incomplete absorption. Repeat the same dose the following day. The treatment will 
be 1 day longer (using tablets from an extra treatment wallet).
  If the vomiting happened more than 2 hours after fexinidazole intake, that dose is 
considered valid and assumed to be sufficiently absorbed.
If a second event of vomiting occurs after administration of any other dose, with or 
without the use of an antiemetic, consider the possibility of changing to an alternative 
treatment. Again, the timing (2 hours after medicine intake) defines the validity of the 
dose taken.
The health care staff responsible for the treatment should ensure that a minimum of 7 
doses, including all during the loading phase (D1–D4), plus at least 3 doses during the 
maintenance phase (D5–D10) are completed correctly.
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5.3. Food concomitant with fexinidazole 
Fexinidazole must always be taken with food in the stomach (i.e. the patient must be 
in a “fed condition”). Taken without food, the absorption is insufficient and the active 
metabolites do not reach therapeutic levels, especially in the central nervous system 
(where the bioavailability is three-fold lower). Therefore, a dose taken without food is 
equal to a dose missed. 
The tablets must be swallowed during or immediately after the main meal of the day, 
within 30 minutes of that meal.  
The amount of food taken is more important than the type of food (fat content, etc.); 
however, liquid food is proscribed because it would drastically decrease fexinidazole 
absorption. The amount considered necessary is defined as a standard breakfast or 
lunch (as a reference, a minimum volume of 250 mL of solid food).
5.4. Directly observed treatment 
Fexinidazole should be administered to all eligible patients only under the strict 
supervision of trained health staff who must confirm that the patient is in a fed condition 
and who must directly observe each drug intake. Treatment can be directly observed 
on an outpatient or inpatient basis, depending on the characteristics of the patient, as 
outlined below.
5.4.1. Outpatient: daily DOT by trained health staff
Outpatient administration of fexinidazole is possible in patients with a low expected risk 
of poor compliance with treatment. Treatment should be directly observed in hospitals 
or peripheral health facilities and can, in particular situations, be directly observed at 
home, but always under the strict supervision of trained health staff who must ensure 
daily compliance of drug intake with food, for the total duration of treatment (10 days).
Fexinidazole can ONLY be given on an outpatient basis when all of the following 
conditions are met: 
  confidence in concomitant food intake;
  confidence in full adherence to treatment;
  absence of psychiatric disorders (history or acute); and
  body weight ≥ 35 kg.
The decision to administer fexinidazole as an outpatient (under daily supervision) should 
be taken in consultation between the patient, his/her family and clinicians, taking the 
above conditions into account.
5.4.2. Inpatient: daily DOT at the hospital bedside
Patients should be hospitalized to receive fexinidazole when the above conditions are 
NOT met.
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5.5. Special populations
Elderly: No dose adjustment is required in patients aged ≥ 65 years.
Renal impairment: No dose adjustment is required for patients with renal impairment. 
Hepatic impairment: Contraindicated (see below). 
Malnutrition or diarrhoea/vomiting: The patient should receive potassium-rich foods 
or potassium chloride tablets in order to compensate for potential hypokalemia.
5.6. Contraindications and warnings
Patients should not be treated with fexinidazole if any one of the following conditions is 
present:
  hypersensitivity to fexinidazole, to any agent of the nitroimidazole class (e.g. 
metronidazole, tinidazole), or to any of the excipients; or .
  jaundice, generalized oedema, bleeding or other clinical signs of hepatic insufficiency 
(e.g. due to liver cirrhosis); or
  risk of QT interval prolongation: patients with congenital prolongation of QT interval, 
uncorrected electrolyte abnormalities (e.g. hypokalemia or hypomagnesaemia), history 
of symptomatic cardiac arrhythmia, clinically relevant bradycardia, severe congestive 
cardiac failure, family history of sudden death or patients with concomitant use of 
medicinal products that prolong QT interval or induce bradycardia or hypokalemia.
Alcohol should not be consumed during treatment with fexinidazole or within 48 
hours of the last dose due to the risk of a disulfiram-like reaction (antabuse effect) 
characterized by flushing, rash, peripheral oedema, nausea and headache. If alcohol is 
consumed concomitant to fexinidazole, severe and potentially fatal cardiorespiratory 
and neurological reactions may occur.
5.7. Adverse reactions
The most frequent adverse reactions to fexinidazole reported in clinical trials were 
vomiting (38% of patients), nausea (33%), asthenia (20%), decreased appetite (17%), 
headache (16%), insomnia (15%), tremor (14%) and dizziness (14%). Vomiting was more 
frequent in children than in adults.
Neuropsychiatric adverse reactions (insomnia, hallucination, agitation, logorrhea, 
abnormal behaviour, anxiety, psychotic disorder) are more frequent with fexinidazole 
than with NECT. Caution should be exercised when using fexinidazole in patients with 
psychiatric disorders (historical or acute) and these patients should be hospitalized 
during the 10-day treatment period.
QT interval prolongation (average increase of 15.4 ms), which may increase the risk for 
ventricular arrhythmias when certain conditions coexist (see sections 5.5. and 5.6).
Neutropenia may occur in patients receiving fexinidazole. Therefore, fexinidazole should 
be used with caution in patients with evidence, or history, of blood dyscrasia. Patients 
should return to the clinic if they develop a fever or clinical signs of suspected infection 
within 3 months of the end of treatment.
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6. Pentamidine
Until now, pentamidine has been the first-choice treatment for first-stage gambiense 
HAT (CSF WBC ≤ 5/µL) and it remains so for children aged < 6 years or body weight  
< 20 kg, or in other patients with CSF WBC count ≤ 5 /µL who cannot receive 
fexinidazole. The cure rate with pentamidine in first-stage HAT is 93–98% and has 
not decreased for decades. Pentamidine is usually given as a deep intramuscular 
injection because of the frequent occurrence of severe hypotension after intravenous 
administration.
6.1. Presentation
Pentamidine is supplied in vials with 300 mg of pentamidine isethionate powder, to be 
reconstituted with 10 mL of water for injection.
6.2. Posology and administration
The dosage is 4 mg/kg once daily for 7 days, administered by intramuscular injection.
The 300 mg pentamidine vial should be diluted in water for injection (10 mL) using a 
syringe (see below), to obtain a final concentration of 30 mg/mL. The dose is calculated 
according to body weight (4 mg/kg).
Note that the capacity of the vial of pentamidine is smaller than 10 mL. The 
recommended procedure is:
  Draw up 10 mL of water for injection into a syringe of 10 mL.
  Inject 3 mL into the pentamidine vial, keep the syringe and mix well. Take this dilution 
into the syringe (mixing it with the remaining water) and repeat the process twice until 
the pentamidine is completely diluted. Finally, draw up the entire preparation into the 
syringe.
  Adjust the volume in the syringe according to the weight of the patient by discarding 
the excess.
Pentamidine is administered intramuscularly (in the gluteal region), with strict respect for 
antiseptic technique and on alternate sides (left–right) each day. 
Patients should be given a source of sugar (e.g. a sweet drink, water with sugar and/or 
biscuits, bananas, mangos) before injection to prevent hypoglycaemia.
Patients should lie down for at least 1 h after injection to prevent symptomatic 
hypotension.
Vital signs should be checked again 1 h after injection and monitored if the patient is 
unwell.
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Weight Dose/day (mg) mL to inject
5 kg 20 mg 0.7 mL
10 kg 40 mg 1.3 mL
15 kg 60 mg 2.0 mL
20 kg 80 mg 2.7 mL
25 kg 100 mg 3.3 mL
30 kg 120 mg 4.0 mL
35 kg 140 mg 4.7 mL
40 kg 160 mg 5.3 mL
45 kg 180 mg 6.0 mL
50 kg 200 mg 6.7 mL
55 kg 220 mg 7.3 mL
60 kg 240 mg 8.0 mL
65 kg 260 mg 8.7 mL
70 kg 280 mg 9.3 mL
75 kg 300 mg 10.0 mL
Table 3. Reference table for pentamidine dosage according to body weight 
6.3. Adverse reactions
Pentamidine is generally well tolerated, although minor adverse reactions are 
common. Possible immediate reactions include hypotension in about 10% of patients, 
with dizziness and sometimes collapse and shock; after intravenous injection, 
hypotension can be as frequent as 75%. Occasional adverse reactions are nausea 
or vomiting and pain at the injection site. Sterile abscesses or necrosis may occur at 
the site of intramuscular injection. Systemic reactions reported include azotaemia 
due to nephrotoxicity, leukopenia, raised liver function enzymes, hypoglycaemia and 
hyperglycaemia. Persistent diabetes is a rare but feared event. Severe adverse events 
such as anaphylaxis and acute pancreatitis are extremely rare.
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7. NECT
Nifurtimox–eflornithine combination therapy, or NECT, is highly effective against second-
stage gambiense HAT, with documented cure rates of 95–98% and fatality rates of < 1%. 
As a drug combination, NECT is believed to avoid selection of drug resistance by the 
parasite. It remains the first-choice treatment for meningo-encephalitic stage gambiense 
HAT with > 100 WBC/µL in CSF and for all children aged < 6 years or body weight < 20 
kg with second-stage gambiense HAT (> 5 WBC/µL in CSF).
NECT consists of oral nifurtimox and intravenous eflornithine (α-difluoromethylornithine 
or DFMO): nifurtimox 15 mg/kg per day orally in three doses for 10 days; eflornithine 400 
mg/kg per day intravenously in two 2-h infusions (each dose diluted in 250 mL of water 
for injection) for 7 days. In children weighing < 10 kg, it should be diluted in 50 mL of 
water for injection. If water for injection is unavailable, eflornithine can be diluted in 5% 
dextrose or in saline.
7.1. Presentation
The NECT kit (comprising medicines and materials for four adults) is distributed by WHO 
to ensure access to treatment for patients affected by gambiense HAT. Each kit contains: 
  eflornithine hydrochloride (Ornidyl) 100 mL (200 mg/mL), 3 boxes of 12 glass vials 
(total 36 vials);
  nifurtimox (Lampit) tablets 120 mg, 3 bottles with 100 tablets each (total of 300 
tablets);
  sterile water for injection, 60 plastic bags of 250 mL each;
  infusion giving set “Y” Luer lock, with air inlet, sterile, 1 box of 60 sets (50 drops per mL);
  catheter, intravenous, single use 20G (1.0 x 32 mm) pink, 1 box with 50 catheters;
  catheter top, Luer male, sterile, 1 box with 100 tops;
  needle, single use, Luer IV, 19G (1.1 x 40 mm), cream, 2 boxes of 100 needles (total 
200 needles);
  syringe, single use, Luer 20 mL, 1 box with 160 syringes;
  syringe, single use, Luer 2 mL, 1 box with 100 syringes;
  compress gauze hydrophilic, sterile 10 cm, 120 compresses; 
  bandage, extensible, 7 cm x 4 m, 1 box with 20 bandages;
  adhesive tape, zinc oxide, perforated 10 cm x 5 m, 1 roll;  
  cotton wool 500 g, 1 roll; 
  povidone iodine 10% 200 mL, 1 bottle; 
  examination gloves, single use, size large, 1 box with 100 gloves;
  examination gloves, single use, size medium, 1 box with 100 gloves;
  tourniquet 100 x 1.8 cm, 2 tourniquets; and
  leaflet, Trypano NECT kit, French and English.
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7.2. Posology and administration
7.2.1. Eflornithine 
Dosage 
Eflornithine is administered by intravenous infusion every 12 h for 7 days. The infusion 
must extend over 2 h. The presentation of Ornidyl is hypertonic and must be diluted 
prior to infusion with sterile water for injection. The dose is calculated according to the 
patient’s body weight: 200 mg/kg every 12 h (Table 4).
Further details regarding pharmacology, safety and adverse reactions appear in the 
manufacturer’s notice provided in each box.
Patient body weight 
(kg)
eflornithine dose (mg) 
Ornidyl to be diluted 
(mL)
Water for injection 
(mL)
Total volume of 
solution to be 
administered (mL)
5 1000 5 50 55
10 2000 10 50 60
15 3000 15 100 115
20 4000 20 100 120
25 5000 25 100 125
30 6000 30 250 280
35 7000 35 250 285
40 8000 40 250 290
45 9000 45 250 295
50 10 000 50 250 300
55 11 000 55 250 305
60 12 000 60 250 310
65 13 000 65 250 315
70 14 000 70 250 320
Table 4. Reference table for eflornithine dosage according to body weight, given every 12 hours
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Administration 
The eflornithine solution must be administered starting within the hour after preparation, 
by intravenous infusion at 50 drops per min. The total time should be around 2 h.
The solution must be administered every 12 h for 7 days to complete the treatment. The 
following practical steps should be taken:
  Label the sterile water for injection bag by writing the name of the patient and/or the 
number of the bed on the adhesive tape that should be fixed on the bag.
  Write down on the water-for-injection bag the dose of eflornithine in mL.     
  Using the 20 mL syringe, extract the quantity of eflornithine (mL) written on the sterile 
water-for-injection bag and inject that amount of eflornithine into the bag.
  Assemble the drip set; let a small quantity of solution flow through the set to remove 
the air bubbles.
  Verify there is no phlebitis.
  Remove the top from the catheter and throw it away (the kit has a box with sterile 
tops).
  Connect the drip set to the catheter.
  Verify the patency of the catheter. At times between administrations the catheter can 
be blocked by a small blood clot. If the solution does not flow, lock the drip set and 
press the rubber. Usually this action will be enough to remove the clot. If this fails, use 
1 mL of sodium chloride with a 2 mL syringe to flush the small blood clots.
  Adjust the infusion rate to 50 drops per min.
  Regularly check the drip rate.
  When the infusion is finished (after 2 h) stop the drip set and remove, then cover the 
catheter with a new sterile top. Tick the drug administration sheet.
  Ensure that the catheter is protected (Figure 3).
  Discard the drip set and the bag in the litter bin.
Replace the cannula for infusion at least every 48 h. The cannulas should be placed 
following strict asepsis and maintained covered by a sterile gauze and fixed with 
adhesive tape.
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Photos: courtesy of F. Chappuis
Figure. 3. Protection of the catheter 
3a. Protect the open 
end of the catheter with 
sterile gauze
3b. Fix the catheter
3c. Protect the catheter 
between two doses
22
7.2.2. Nifurtimox 
Dosage 
Nifurtimox is administered orally every 8 h for 10 days. The dose is calculated according 
to the patient’s weight: 5 mg/kg every 8 h (total daily dose of 15 mg/kg). Tablets may be 
cut to obtain the correct dose or, if needed, crushed and diluted into food or water with 
sugar to facilitate their intake.
Body weight (kg) No. of tablets/8 h
6–7 ¼ ¼ ¼
8–9 ½ ¼ ¼
10–11 ½ ½ ¼
12 ½ ½ ½
13–14 ¾ ½ ½
15–16 ¾ ¾ ½
17–18 ¾ ¾ ¾
19–20 1 ¾ ¾
21–22 1 1 ¾
23–24 1 1 1
25–26 1¼ 1 1
27–28 1¼ 1¼ 1
29–31 1¼ 1¼ 1¼
32–33 1½ 1¼ 1¼
34–35 1½ 1½ 1¼
36–37 1½ 1½ 1½
38–39 1¾ 1½ 1½
40–41 1¾ 1¾ 1½
42–43 1¾ 1¾ 1¾
Table 5. Reference table for nifurtimox dosage according to body weight, given every 8 hours
Body weight (kg) No. of tablets/8 h
44–45 2 1¾ 1¾
46–47 2 2 1¾
48–49 2 2 2
50–51 2¼ 2 2
52–53 2¼ 2¼ 2
54–55 2¼ 2¼ 2¼
56–57 2¼ 2¼ 2½
58–59 2½ 2¼ 2½
60–61 2½ 2½ 2½
62–63 2¾ 2½ 2½
64–65 2¾ 2¾ 2½
66–67 2¾ 2¾ 2¾
68–69 3 2¾ 2¾
70–71 3 3 2¾
72–73 3 3 3
74–75 3¼ 3 3
76–77 3¼ 3¼ 3
78–79 3¼ 3¼ 3¼
80–81 3½ 3¼ 3¼
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Administration 
Nifurtimox must be administered under strict supervision to ensure that the patient 
swallows the tablets, preferably after a meal, and to check if vomiting occurs. If vomiting 
occurs within 30 min after swallowing the tablets, the same dose must be repeated. If 
it occurs 30–60 min after the intake, a half dose should be administered. If it occurs 1 
h after the medicine was taken, then it is considered that the medicine has been fully 
absorbed. If intense nausea or vomiting persists, consider giving domperidone or 
metoclopramide before subsequent nifurtimox administrations. 
7.3. Stopping and resuming treatment with NECT
  If treatment was interrupted for 24 h or less (≤ 2 doses of eflornithine or ≤ 3 doses 
of nifurtimox), the missing doses should be added at the end of the treatment. The 
patient will therefore receive the total of 14 doses of eflornithine and 30 doses of 
nifurtimox that were initially planned.
  If treatment was suspended for more than 24 h (> 2 doses of eflornithine or > 3 doses 
of nifurtimox), nifurtimox should still be administered until a total of 30 doses is 
reached. ONLY eflornithine will be adjusted as follows: 
  If the patient received < 6 doses of eflornithine, then a new course of 14 doses 
should be started.  
  If the patient received 6–12 doses, 4 additional doses of eflornithine should be 
added at the end of the treatment, so that a total of 18 doses are administered.
  If the patient already received > 12 doses of eflornithine, then the treatment 
should be continued with nifurtimox only.
7.4. Adverse reactions
Adverse reactions after treatment with NECT are similar to those of monotherapy with 
eflornithine (see section 8.3) and nifurtimox but are generally better tolerated than those 
associated with eflornithine monotherapy. NECT is better tolerated in children than 
in adults. The most common adverse reactions are abdominal pain, nausea, vomiting 
and headache. There is a risk of seizures, and occasionally psychotic reactions and 
hallucinations. Diarrhoea and vomiting are frequent (> 50% of treated patients) but do 
not warrant cessation of treatment. Other described adverse effects are: tremor (5–10%), 
headache, bone marrow suppression (anaemia, leucopenia), vertigo and ear troubles.
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8. Eflornithine monotherapy
Eflornithine is given as a monotherapy for second-stage gambiense HAT when NECT is 
not feasible because the companion drug nifurtimox is unavailable or contraindicated 
and when, additionally, fexinidazole cannot be given. Cure rates are 90–95% and fatality 
rates < 2%. Eflornithine is both cytostatic (i.e. it affects the host’s cells) and trypanostatic 
(i.e. it affects trypanosome metabolism preventing cell division). An active immune 
system is required to achieve cure: in patients who are immunocompromised, parasite 
elimination might not be complete with eflornithine alone.
8.1. Presentation
Eflornithine hydrochloride (Ornidyl) is supplied in 100 mL vials (200 mg/mL), packed in 
boxes of 12 vials.
8.2. Posology and administration
As monotherapy, eflornithine is administered as a slow intravenous infusion every 6 h for 
14 days (56 infusions in total). The dosage is 400 mg/kg per day intravenously, divided 
into four 2-h infusions (each dose diluted, preferably in 100 mL of water for injection) for 
14 days. In children weighing < 10 kg, it is diluted in 50 mL of water for injection. If water 
for injection is unavailable, eflornithine can be diluted in 5% dextrose or in saline.
The dose is calculated according to the patient’s weight: 100 mg/kg every 6 h (Table 6).
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8.3. Adverse reactions
Adverse reactions are frequent and similar to those of other cytostatics (including 
diarrhoea and neutropenia). The main adverse reactions are fever, pruritus, hypertension, 
nausea, vomiting, diarrhoea, abdominal pain, headaches, myelosuppression (anaemia, 
leucopenia, thrombocytopenia) and, more rarely, seizures that are generally isolated and 
respond to treatment.
Body weight (kg)
Eflornithine dose 
(mg) 
Ornidyl to be 
diluted (mL)
Water for 
injection (mL)
Total volume of solution to be 
administered (mL)
5 500 2.5 50 52.5
10 1000 5 50 55
15 1500 7.5 100 107.5
20 2000 10 100 110
25 2500 12.5 100 112.5
30 3000 15 100 115
35 3500 17.5 100 117.5
40 4000 20 100 120
45 4500 22.5 100 123.5
50 5000 25 100 127
55 5500 27.5 100 130.5
60 6000 30 100 134
65 6500 32.5 100 137.5
70 7000 35 100 141
 
a For details regarding administration, see section 7.1.
Table 6.  Reference table for eflornithine dosage according to body weight, given every 6 hoursa
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9. Melarsoprol
Another treatment option is melarsoprol, which has variable efficacy (due to parasite 
resistance) and a fatality rate of about 6%. Given the high frequency of severe, life-
threatening adverse reactions, the only remaining indication in gambiense HAT is the 
treatment of recurrent relapse after first-line and rescue treatments (including NECT, 
NECT-long, fexinidazole or eflornithine monotherapy, as appropriate). 
9.1. Posology and administration
Melarsoprol (Arsobal) is available in a 5 mL ampoule containing 180 mg of melarsoprol 
dissolved in propylene glycol (36 mg/mL). The dosage is 2.2 mg/kg per day (maximum: 5 
mL) in slow intravenous injections once daily for 10 days (Table 7).
Body weight (kg) Melarsoprol dose (mg) Arsobal to inject (mL)
10 22 0.6
15 33 0.9
20 44 1.2
25 55 1.5
30 66 1.8
35 77 2.1
40 88 2.4
45 99 2.8
50 110 3.1
55 121 3.4
60 132 3.7
65 143 4.0
70 154 4.3
75 165 4.6
80 176 4.9
>80 180 5.0
Table 7.  Reference table for melarsoprol dosage 
according to body weight, given once daily
The medicine should be administered with oral prednisolone 1 mg/kg per day 
(maximum dose 50 mg) for 12 days, tapering the dosage in the last 3 days (Table 8). 
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Melarsoprol cannot be prepared with water, or come into contact with water, which may 
cause precipitation. If conditions are appropriate (i.e. good sterilization procedures are 
followed), it is better to use sterile, dry glass syringes to draw up and inject melarsoprol. 
After use, these syringes must be washed, dried and sterilized. Care must be taken 
when using melarsoprol in plastic syringes; after drawing up the liquid (at the patient’s 
bedside) it must be administered immediately (but slowly). A few brands of plastic 
syringes show signs of deterioration when used with melarsoprol. It is best given 
intravenously via a micro-profuser (butterfly) as a SLOW push. The injection is very 
painful, and the subsequent local reaction means that another intravenous site and 
line must be used for the next dose. Melarsoprol should preferably be administered by 
health care personnel with experience in use of this drug and under careful supervision.
9.2. Adverse reactions
The most important serious reaction is an encephalopathic syndrome that occurs in 
5–18% of all treated cases and is fatal in 10–70% of affected patients. Co-administration 
of prednisolone might have a protective effect against the immune reaction thought 
to be a component of the encephalopathic syndrome. The encephalopathic syndrome 
usually occurs 7–14 days after the first injection and is characterized by fever and 
convulsions, rapid onset of neurological disorders, progressive coma or abnormal 
behaviour. Close monitoring of patients might allow detection of early signs, such as 
fever or headache, or both, prompting the cessation of melarsoprol and management 
with dexamethasone and diazepam. Other frequent adverse reactions include general 
malaise and gastrointestinal (nausea, vomiting and diarrhoea) and skin reactions 
(pruritus); severe complications, such as exfoliative dermatitis, occur in fewer than 1% of 
cases. Cardiac failure is common and can be fatal, but it might be attributable to HAT 
itself.
Day Prednisolone (PO) Melarsoprol (IV)
D1 1 mg/kg 2.2 mg/kg
D2 1 mg/kg 2.2 mg/kg
D3 1 mg/kg 2.2 mg/kg
D4 1 mg/kg 2.2 mg/kg
D5 1 mg/kg 2.2 mg/kg
D6 1 mg/kg 2.2 mg/kg
D7 1 mg/kg 2.2 mg/kg
D8 1 mg/kg 2.2 mg/kg
D9 1 mg/kg 2.2 mg/kg
D10 0.75 mg/kg 2.2 mg/kg
D11 0.5 mg/kg STOP
D12 0.25 mg/kg
D13 STOP
Table 8.  Reference table for melarsoprol treatment 
schedule, with concomitant prednisolone
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10. Treatment in pregnancy
Recommendations for anti-trypanosomal treatment during pregnancy and lactation are 
based on clinical practice rather than on solid evidence. Pentamidine and fexinidazole 
can be given after the first trimester. Melarsoprol, eflornithine and nifurtimox are all 
theoretically contraindicated, and their use and treatment timing (stage of pregnancy) 
depend on the general condition of the mother. If her general condition allows for 
watchful waiting, regular (at least monthly) clinical assessment is advised. Fexinidazole 
or pentamidine should be administered, with the main objective of reducing the risk 
of vertical transmission of the disease. NECT should generally be administered after 
delivery. If the general condition of the pregnant woman is moderately or severely 
altered, treatment with fexinidazole, eflornithine alone or NECT must be administered 
with the main objective of saving her life. The benefits and risks must be clearly 
explained to the patient and her relatives. After delivery, the newborn should be 
examined clinically and checked for the presence of circulating trypanosomes in the 
blood. Breastfeeding should continue during HAT treatment.
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11. Follow-up after treatment
The assessment of treatment outcome requires following up the patient for up to 24 
months, as relapses may occur more than a year after treatment. 
In patients treated with pentamidine and NECT, systematic and active follow-up is not 
recommended, owing to the high efficacy of these therapies, where good compliance 
with the full schedule is guaranteed because of being injectable. Instead, patients are 
to be advised to come for check-up if symptoms reappear (see WHO Technical Report 
Series, No. 984, 2013).
Because fexinidazole is a new medicine, and given the risk of insufficient compliance 
with the full treatment schedule and/or with the concomitant food intake which is 
essential for drug absorption, the interest of systematic follow-up is high. In patients 
treated with fexinidazole, relapses may occur late, even 12–24 months after treatment. 
Therefore, it is recommended that these patients be asked to attend for general 
examination at 6, 12, 18 and 24 months, or at any time if symptoms reappear. If signs 
or symptoms suggest a possibility of relapse, laboratory examinations of body fluids, 
including CSF, should be performed in order to detect trypanosomes and/or CSF 
leukocytosis.
A relapse will be defined by the presence of trypanosomes in any body fluid or tissue. 
When trypanosomes are not seen, a high WBC count in CSF (regardless of counts at first 
diagnosis) will be considered a relapse according to the following criteria:
  0–4 months post-treatment:  
   the WBC count in CSF does not provide reliable information; diagnosis of relapse 
is based only on the observation of parasites.
  6 months post-treatment (5–9-month window):   
   6–49 WBC/µL of CSF: The evolution is uncertain and a new follow-up at 12 months 
is strongly recommended. Rescue treatment could be considered by the clinician 
if clinical features suggest relapse.
  ≥ 50 WBC/µL of CSF: Relapse; rescue treatment needed.
  12 months post-treatment or later (10–24-month window):
   20 WBC/µL of CSF: Relapse; rescue treatment needed.
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12. Treatment of relapses
A summary of rescue treatments after relapse is shown in Table 1 (section 4.5).
If a patient treated with fexinidazole relapses, then NECT should be given.
If a patient treated with pentamidine relapses, fexinidazole or NECT should be 
administered depending on the patient’s age/weight and the CSF WBC count. 
If after NECT the patient relapses, the first rescue treatment should be NECT-long, which 
comprises eflornithine infusions (400 mg/kg per day in two infusions) for a total of 14 
days, and nifurtimox given for 10 days, exactly as in the NECT schedule. The treatment 
alternatives are eflornithine monotherapy at 100 mg/kg every 6 h (400 mg/kg per day) 
for 14 days, or fexinidazole if age/weight appropriate and WBC in CSF < 100 cells 
(compassionate use).
If the patient relapses after the above rescue treatments, then melarsoprol should be 
considered as a last treatment option due to its toxicity. 
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Annexes
Annex 1: Symptoms and signs consistent with severe HAT
After a patient has been diagnosed with gambiense HAT, a detailed clinical assessment 
must be carried out by health staff to establish the presence or absence of symptoms 
and signs which can raise suspicion of severe HAT (i.e. ≥ 100 CSF WBC/µL). The 
objective of the clinical assessment is not to “diagnose” severe HAT, but to direct the 
patient to further laboratory examinations (i.e. lumbar puncture) which can determine 
the severity of the disease more precisely and guide treatment decisions. Conversely, in 
patients not presenting with these clinical features, a lumbar puncture may be avoided 
and treatment with fexinidazole can be initiated. 
The symptoms and signs raising a suspicion of severe HAT are: 
Mental confusion: disorientation in time and/or space, inattention, slowed thought processes, 
memory problems.
Abnormal behaviour: manifestly abnormal, inappropriate and/or unusual behaviour for that 
patient, such as disinhibition, excitement, euphoria, aggressiveness or indifference.
Logorrhea: excessive, incontrollable or incoherent speech.
Anxiety: constant anxiety, nervousness and worry about everything occurring in the patient’s 
life.
Ataxia: loss of muscle control in the arms and legs, which may lead to a lack of balance and 
coordination and, possibly, a disturbance of gait. Ataxia may affect the fingers, hands, arms, 
legs, body, speech and even eye movements.
Tremor: involuntary twitching movements of one or more body parts.
Motor weakness: weakness in one or more muscles groups, usually the limbs and/or trunk.
Speech impairment: inability to speak and articulate words normally.
Abnormal gait: the patient cannot walk normally.
Abnormal movements: uncontrollable and abnormal movements which can affect the limbs, 
trunk, face or neck, such as facial grimacing, tremor, chorea and/or athetosis in the limbs, 
which may also be observed during walking or on clinical examination.
Seizures: uncontrolled shaking movements involving much of the body with loss of 
consciousness (tonic-clonic seizure), or shaking movements involving only part of the body 
with variable levels of consciousness (focal seizure).
Note: Sleep disorder is a frequent clinical feature that is very common in severe HAT, 
but also frequently present in non-severe HAT. Therefore, this feature alone cannot 
determine the need for a lumbar puncture.
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Annex 2: Guideline development methods
These WHO guidelines were developed in accordance with the recommendations 
of the WHO handbook for guideline development1 following the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) framework. A 
Guideline Development Group (GDG) was created, including experts with recognized 
work in the field of treatment of HAT and other similar and/or related pathologies, but 
also in public health related issues, from different institutions. The group comprised 
experts from endemic countries in sub-Saharan Africa working in the national sleeping 
sickness control programmes and with vast experience in managing HAT cases. 
Geographical representation and gender balance were also considerations in selecting 
members. An initial scoping and planning process was used to formulate key questions 
about HAT treatment and determine patient-important outcomes. These questions were 
structured in PICO (population, intervention, comparator and outcomes) format. 
The PICO questions were: 
1 Should fexinidazole vs pentamidine be used for first-stage HAT?
2a
Should fexinidazole (oral) vs NECT (oral/intravenous) be used for people with HAT 
that have ≤ 100 WBC in CSF?
2b
Should fexinidazole (oral) vs NECT (oral/intravenous) be used for people with HAT 
that have > 100 WBC in CSF?
3 Should clinical stratification vs no stratification be used for people with HAT?
4
Should inpatient administration vs outpatient administration under supervision be 
used for people with HAT being treated with fexinidazole? 
 
CSF, cerebrospinal fluid; NECT, nifurtimox–eflornithine combination therapy; WBC, white blood cell
Systematic evidence reviews were commissioned externally to address the questions. 
Criteria for inclusion and exclusion of the literature reviewed (e.g. study design, 
sample size, duration of follow up) were based on the evidence needed to answer the 
PICO questions. Search strategies and summaries of evidence are reported in Web 
appendix 1. The GRADE methodology was used to assess evidence certainty, which was 
categorized per outcome and per PICO question as high, moderate, low or very low, 
considering the following factors: risk of bias, indirectness, imprecision, inconsistency 
and publication bias. 
The development of recommendations followed the GRADE methodology. For each 
PICO question the GDG reviewed the available evidence and made judgements for 
each of the following aspects: desirable effects, undesirable effects, evidence certainty, 
values, balance of effects, resources required, impact on equity, acceptability and 
1 WHO handbook for guideline development, 2nd edition. Geneva: World Health Organization; 2014 (http://apps.who.int/
medicinedocs/documents/s22083en/s22083en.pdf, accessed June 2019).
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feasibility. Based on this judgement, the GDG decided on the direction (in favour vs 
against) and the strength (strong vs conditional) of the recommendation. The discussion 
was guided by the GRADE Evidence to Decision Tables (EtD).1 The GDG also used 
these tables to provide additional information, as needed, on: justification, subgroup 
considerations, monitoring and evaluation, and research priorities.
Decision-making mechanism
Discussions were facilitated by the chair and co-chair (guideline methodologist), with 
emphasis on giving equal voice to all panel members. The final recommendations 
were drafted by consensus (full agreement by all members). When consensus was not 
reached, the GDG used anonymous voting, and the relevant discrepancies were noted 
in the EtD tables.
Consideration of potential harms and unintended consequences
When developing the PICO questions, the steering committee considered potential 
harms and unintended consequences as part of the outcomes of interest. Subsequently, 
the systematic reviewers searched for, synthesized and rated the certainty of evidence 
about potential consequences, which was included in the evidence profiles and EtD 
tables. The GDG reviewed that evidence and made judgements about the “undesirable 
effects” and later about the “balance of desirable and undesirable effects”. They 
also discussed how to mitigate the risks and unintended consequences. Those 
judgements contributed to the GDG’s decision on the direction and strength of the 
recommendations.
Recommended new procedure for choosing the treatment
The WHO panel suggested doing lumbar puncture (LP) stratification over not doing LP 
stratification in patients diagnosed with HAT, which is in line with the scientific opinion 
of the European Medicines Agency. However, it recommended a two-step stratification 
(first, clinical; second, LP) whereby LP is reserved for patients presenting clinical features 
leading to the suspicion of severe second-stage HAT, who should be evaluated via LP 
to ensure they receive the most appropriate treatment. A subgroup of patients not 
presenting such clinical features can be spared the LP and be treated with fexinidazole. 
This decision reduces the risk associated with LP in an important number of patients for 
whom it is considered that fexinidazole has similar efficacy to the current treatment. The 
only potential harm/unintended consequence identified is the possible error of clinical 
judgement in a disease presenting high variability of clinical manifestations, which would 
lead to the prescription of fexinidazole to patients for whom NECT is more appropriate. 
This risk was minimized by recommending LP when any neurological abnormality is 
observed, and by preparing a checklist of key neuropathy features to be assessed 
at field level. Moreover, it was also recommended that all medical staff treating HAT 
patients receive specific training. Finally, it was recommended that patients receiving 
fexinidazole should be followed up 6-monthly for 24 months post-treatment, in order to 
detect relapses early.
1 Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Working Group. GRADE 
Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 
BMJ. 2016;28:353.
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a WHO declaration of interests (DOI) form, including any participation in consulting 
and advisory panels, research support and financial investments. The WHO Secretariat 
assessed the declarations submitted and having observed no significant financial, 
commercial or intellectual conflicts of interests concluded that no member should be 
excluded from actively taking part in formulating the recommendations. For the peer 
review group, the WHO Secretariat was satisfied that there had been a transparent 
declaration of interests, and no case necessitated exclusion from the review process. 
At the meeting of the GDG in December 2018, all participants verbally disclosed any 
interests declared to the rest of the group. Hence, the GDG was aware of any existing 
interests among its members. The evidence review team was contracted via the 
Cochrane Collaboration with specific terms of reference. Researchers involved in the 
review were also required to complete WHO DOI, which were assessed and cleared by 
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Dissemination plan
A publication plan was approved in the WHO e-Pub system, including hard copies and 
availability online. The guidelines will be accessible on the WHO website with links to 
other related websites and translated into the official UN languages pertinent to the 
HAT field. Hard copies will be distributed through national HAT control programmes 
to health staff working on case management. The Secretariat will work with the WHO 
regional offices to ensure dissemination to WHO country offices and ministries of health, 
as well as key international and national collaborating centres. Additional tools will be 
developed to support country implementation. 
Incorporation of these guidelines into the national treatment protocols and 
implementation in the field will be monitored via the ongoing support activities, and 
through the annual WHO coordination meeting of HAT endemic countries.
As stated in the introductory section, the present guidelines are considered 
interim guidelines because new information is expected in the near future from 
pharmacovigilance and ongoing studies, particularly on oral drugs. An update to these 
guidelines is therefore planned within a few years.
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